Exercise Training in Chagas Cardiomyopathy

A Randomized Trial of the Effects of Exercise Training in Chagas Cardiomyopathy

NCT01006473•Federal University of Minas Gerais

Summary

The benefits of exercise training in heart failure are well established. Its effects, however, have not been evaluated in Chagas cardiomyopathy (ChC). The investigators hypothesis is that the exercise training may improve functional capacity, quality of life (QoL), and reduce brain natriuretic peptide (BNP) levels in patients with ChC.

Eligibility

Age

30 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Chronic Chagas dilated cardiomyopathy, defined by the echocardiography finding of a dilated left ventricle with moderate or severe impaired left ventricular systolic function (left ventricular ejection fraction ≤ 45%).
•To be clinically stable for at least 3 months
•To have sinus rhythm
•To be under standard medical therapy use at the time.

Exclusion Criteria

•Inability to attend regular exercise training
•The presence of a pacemaker, associated cardiac or systemic diseases
•Practitioners of regular physical activity

Locations (1)

Federal University of Minas Gerais

Belo Horizonte, Minas Gerais, Brazil

Key Dates

Start Date

March 1, 2007

Primary Completion Date

March 1, 2008

Completion Date

March 1, 2009

Last Updated

August 13, 2015

Enrollment

ACTUAL participants

Conditions

Chagas DiseaseCardiomyopathyExercise Training

Interventions

Exercise training

OTHER

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

RECRUITINGPHASE1/PHASE2

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

NCT05836259

Hypertrophic Cardiomyopathy

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 13, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Exercise Training in Chagas Cardiomyopathy

Inclusion Criteria

Exclusion Criteria

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

HCMR Re-Imaging Study

Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy